Food News and Research

RSS

Experts say propylthiouracil should not longer be used as first-line treatment for Graves' disease in children

Of the 4000 children with Graves' disease treated in the U.S. annually, 40 percent are routinely treated with the drug propylthiouracil.

16 Apr 2009

South Australian hospital battles to contain superbug VRE

The cancer ward at the Royal Adelaide Hospital (RAH) in South Australia is currently battling to cope with an antibiotic-resistant bacteria called Vanocomycin-resistant Enterococci (VRE), a form of bacteria which lives in the gut.

16 Apr 2009

3 events offer hope for people with brain tumors

People with brain tumors, and those who love and care for them, will observe Brain Tumor Awareness Week with three educational and celebratory events sponsored by the University of Rochester Medical Center and James P. Wilmot Cancer Center.

16 Apr 2009

Separating the good from the bad

Scientists at MIT and Brown University studying how marine bacteria move recently discovered that a sharp variation in water current segregates right-handed bacteria from their left-handed brethren, impelling the microbes in opposite directions.

15 Apr 2009

More reasons to eat green vegetables

Vegetables in the Brassica family -- such as broccoli, cabbage, kale and Brussels sprouts -- are inexpensive yet very nutritive, providing beneficial phytochemicals as well as vitamins, minerals and fiber, according to a report presented in the Comprehensive Reviews in Food Science and Food Safety , a peer reviewed publication of the Institute of Food Technologists (IFT).

15 Apr 2009

Griddle and microwave-cooking maintains highest levels of antioxidants in vegetables

Some vegetable cooking methods may be better than others when it comes to maintaining beneficial antioxidant levels, according to a new study in the Journal of Food Science, published by the Institute of Food Technologists.

15 Apr 2009

Vaccine for Coeliac disease could mean the end of gluten free diets

Australian scientists have developed an experimental vaccine to treat coeliac disease. The team at the Walter and Eliza Hall (WEHI) Institute in Melbourne are hoping a phase 1 clinical trial of the vaccine, due to begin this month, will eventually lead to an effective clinical treatment for the disease.

15 Apr 2009

Many consumers ignore food product recalls

Rutgers' Food Policy Institute (FPI) released a study today showing that many Americans fail to check their homes for recalled food products.

14 Apr 2009

Enteral tube feeding for older patients with advanced dementia

Family members grappling with the decision to allow a feeding tube for a relative with advanced dementia will find little comfort from a new review of evidence.

14 Apr 2009

Mylan confirms first-to-file patent challenge relating to Xeloda

Mylan Inc. has confirmed that the company and its subsidiary Mylan Pharmaceuticals Inc. have been sued by Hoffmann-La Roche Inc. in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Capecitabine Tablets, 150 mg and 500 mg, the generic version of Xeloda Tablets, a chemotherapy treatment for breast and colorectal cancer.

14 Apr 2009

Vaccine for Enterotoxigenic E. coli developed

A Michigan State University researcher has developed a working vaccine for a strain of E. coli that kills 2 million to 3 million children each year in the developing world.

14 Apr 2009

FDA imposes restrictions on Coast IRB due to violations

The U.S Food and Drug Administration has announced that Coast IRB, LLC of Colorado Springs, Colo., has agreed to voluntarily halt some aspects of its clinical trial oversight operations due to serious concerns about the company's ability to protect human subjects participating in clinical trials.

14 Apr 2009

Health Canada approves Simponi (golimumab) for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis

Centocor Ortho Biotech Inc. and Schering-Plough Corporation has announced that Health Canada has granted approval of Simponi (golimumab) as a once-monthly, subcutaneous therapy for the treatment of moderately to severely active rheumatoid arthritis (RA), active psoriatic arthritis (PsA) and active ankylosing spondylitis (AS).

13 Apr 2009